As shown in Figure 5B, patients in the unmarried group have poorer or borderline BCSS than those in the married group with HR+/HER2– (HR =1.512, 95% CI: 1.255–1.82, p < 0.001) breast cancer or HR–/HER2– (HR = 1.205, 95% CI: 0.960–1.512, p = 0.0983), while no significant differences between the married and unmarried groups were found for patients with HR+/HER2 + or HR–/HER2 + breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.